Research Associate/ Senior Research Associate
We are a multi-disciplinary translational prostate cancer research group based at the new University of Cambridge Early Cancer Institute. We are looking for an exceptional postdoctoral researcher to take a leading role in developing cellular models of early high-risk disease, and explore therapeutic responses to novel therapies including DNA damaging agents, using CRISPR-Cas9 based strategies.
The aim of the group’s research is to transform the lives of prostate cancer sufferers. This is achieved through the development and application of cutting-edge technologies including; patient-derived organoids, functional genomic screening, and application of single-cell and -omic sequencing approaches to clinical trial specimens. The translational research team benefits from unparalleled access to surgical biomaterials from diagnostic pathways and clinical trials (NCT02324998, NCT05367440), and our membership of the Alliance for Cancer Early Detection, the International Cancer Genome Consortium, and status as an AstraZeneca Partner of Choice.
This postdoctoral researcher will lead the exciting second phase of development in the prostate cancer CRISPR-Cas9 dynamic screening platform (ProCASP). This will involve further characterisation and optimisation of patient-derived organoids using bespoke and proprietary workflows, and ultimately through the application of bespoke gene editing strategies, the identification of early genetic determinants of prostate cancer survival. This strategy will be used to explore mediators of response to clinically relevant therapies, in particular DNA damaging agents (e.g. PARP1/anti-androgen inhibitor combination therapy). This provides a unique opportunity to discover new insights into the underlying mechanisms that contribute to genome instability and treatment responsiveness, with a view to translating these insights into ongoing trials here in Cambridge.
The successful candidate’s role will also involve supporting the analysis and integration of multi-omic data from related projects with the wider team, to further leverage insights gained from genome-wide and focused CRISPR-screening strategies. Hence, this work is at the exciting translational interface of prostate cancer and DNA repair biology, with clear line-of-sight to defining clinical biomarkers and delivering personalised therapies.
Your work will be supported by academic and clinical mentors, working alongside computational and experimental researchers. Effective coordination with colleagues and collaborators will be key in this role, as will enthusiasm and innovative thinking to maximise impact in these multidisciplinary projects.
Apply online
Closing date
2 November 2022
The aim of the group’s research is to transform the lives of prostate cancer sufferers. This is achieved through the development and application of cutting-edge technologies including; patient-derived organoids, functional genomic screening, and application of single-cell and -omic sequencing approaches to clinical trial specimens. The translational research team benefits from unparalleled access to surgical biomaterials from diagnostic pathways and clinical trials (NCT02324998, NCT05367440), and our membership of the Alliance for Cancer Early Detection, the International Cancer Genome Consortium, and status as an AstraZeneca Partner of Choice.
This postdoctoral researcher will lead the exciting second phase of development in the prostate cancer CRISPR-Cas9 dynamic screening platform (ProCASP). This will involve further characterisation and optimisation of patient-derived organoids using bespoke and proprietary workflows, and ultimately through the application of bespoke gene editing strategies, the identification of early genetic determinants of prostate cancer survival. This strategy will be used to explore mediators of response to clinically relevant therapies, in particular DNA damaging agents (e.g. PARP1/anti-androgen inhibitor combination therapy). This provides a unique opportunity to discover new insights into the underlying mechanisms that contribute to genome instability and treatment responsiveness, with a view to translating these insights into ongoing trials here in Cambridge.
The successful candidate’s role will also involve supporting the analysis and integration of multi-omic data from related projects with the wider team, to further leverage insights gained from genome-wide and focused CRISPR-screening strategies. Hence, this work is at the exciting translational interface of prostate cancer and DNA repair biology, with clear line-of-sight to defining clinical biomarkers and delivering personalised therapies.
Your work will be supported by academic and clinical mentors, working alongside computational and experimental researchers. Effective coordination with colleagues and collaborators will be key in this role, as will enthusiasm and innovative thinking to maximise impact in these multidisciplinary projects.
Apply online
Closing date
2 November 2022
